Corus CAD regulatory update

CardioDx said data from a health economics study showed its Corus CAD gene expression test as a first-line test prior to invasive or non-invasive imaging is cost-effective for assessing non-diabetic patients presenting with symptoms suggestive of coronary artery disease (CAD). Specifically, CardioDx said the study found that using Corus CAD to identify patients in need of referral to myocardial perfusion imaging or invasive coronary angiography is cost-effective at $72,202 per quality adjusted life year (QALY) gained "in a patient cohort closely resembling the commercial intended population for Corus CAD." CardioDx said medical treatments in the U.S. are typically considered cost-effective at <$100,000 per QALY gained. Data were presented at the Society for Medical Decision Making meeting in Phoenix. ...